Valerie Fauvelle
General Counsel chez CHINOOK THERAPEUTICS, INC.
Profil
Valerie Fauvelle is a professional who currently holds the position of Senior Vice President-Regulatory Affairs at Chinook Therapeutics, Inc. She has previously worked as Senior Director-Regulatory Affairs at Cascadian Therapeutics LLC and as Vice President-Regulatory Affairs at Rainier Therapeutics, Inc. Fauvelle has an undergraduate degree from the University of Washington and a graduate degree from George Washington University School of Medicine & Health.
Postes actifs de Valerie Fauvelle
| Sociétés | Poste | Début |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | General Counsel | - |
Anciens postes connus de Valerie Fauvelle
| Sociétés | Poste | Fin |
|---|---|---|
| CASCADIAN THERAPEUTICS INC (USA) | General Counsel | - |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | General Counsel | - |
Formation de Valerie Fauvelle
| University of Washington | Undergraduate Degree |
| George Washington University School of Medicine & Health | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
